Vanda Pharmaceuticals | VNDA - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Akebia Therapeutics USD 32.61M 8.98M 2025-12
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Anika Therapeutics USD 133.9M 9.56M 2026-03
Arrowhead Research USD 568.42M 102.37M 2025-12
AstraZeneca USD 47.33B 1.33B 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Esperion Therapeutics USD -301.96M 149.4M 2025-12
Halozyme Therapeutics USD 48.81M 455.1M 2025-12
Heron Therapeutics USD 13.28M 1.6M 2025-12
Insmed USD 738.98M 206.6M 2025-12
J&J USD 81.19B 358M 2026-03
Lexicon Pharmaceuticals USD 107.54M 12.62M 2025-12
Ligand Pharmaceuticals USD 1.02B 67.04M 2025-12
Merck USD 45.88B 6.73B 2026-03
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Moderna USD 7.41B 1.24B 2026-03
Novartis USD 46.13B 1.8B 2025-12
Pfizer USD 90.1B 3.63B 2026-03
PTC Therapeutics USD -205.31M 49.56M 2025-12
Puma Biotechnology USD 115.27M 10.55M 2025-09
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 72.81B 1.1B 2026-03
Takeda JPY 7.64T 513.39B 2025-12
Teva Pharmaceutical Industries USD 8.23B 314M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12
Veracyte USD 1.31B 51.91M 2025-12